このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Centogene マネジメント

マネジメント基準チェック /24

Centogene'sの CEO はKim Strattonで、 Dec2021年に任命され、の在任期間は 2.5年です。の年間総報酬は€ 2.84Mで、 24.1%給与と75.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.2%を直接所有しており、その価値は€ 120.64K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と5.6年です。

主要情報

Kim Stratton

最高経営責任者

€2.8m

報酬総額

CEO給与比率	24.1%
CEO在任期間	2.5yrs
CEOの所有権	1.2%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	5.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Centogene の収益と比較して、Kim Stratton の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€3m	€684k	-€36m
Sep 30 2023	n/a	n/a	-€38m
Jun 30 2023	n/a	n/a	-€40m
Mar 31 2023	n/a	n/a	-€40m
Dec 31 2022	€2m	€861k	-€39m

報酬と市場: Kimの総報酬 ($USD 3.04M ) は、 German市場 ($USD 419.73K ) の同規模の企業の平均を上回っています。

報酬と収益: Kimの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Kim Stratton (62 yo)

2.5yrs

在職期間

€2,843,000

報酬

Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board and served as its Interim Chief Executive Officer since December 20...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kim Stratton	CEO & Member of Management Board	2.5yrs	€2.84m	1.2% € 120.6k
Jose Miguel Rios	CFO, Legal & IT and Member of Management Board	2.3yrs	€1.13m	0.48% € 48.3k
Peter Bauer	Interim MD	1.4yrs	€376.00k	0.079% € 7.9k
Andrin Oswald	Advisor	2.5yrs	€871.00k	データなし
Ian Rentsch	Chief Commercial Officer & GM of Pharma	1.3yrs	データなし	データなし

2.3yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: 39Kの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Eric Souêtre	Independent Member of the Supervisory Board	7.4yrs	€20.00k	データなし
Hubert Birner	Independent Member of the Supervisory Board	6.9yrs	€22.00k	データなし
Peer Schatz	Independent Chairman of the Supervisory Board	4.3yrs	€717.00k	0.26% € 25.9k
Jonathan Sheldon	Independent Member of the Supervisory Board	3.5yrs	€97.00k	データなし
Guido Prehn	Independent Member of the Supervisory Board	7.4yrs	€20.00k	データなし
Mary Sheahan	Independent Member of the Supervisory Board	1.5yrs	€239.00k	データなし

5.6yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 39Kの取締役会は経験豊富であると考えられます ( 5.6年の平均在任期間)。

Centogene マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Recent updates

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021)

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings released: €0.44 loss per share (vs €0.37 loss in 2Q 2021)

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021)

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.09 loss per share (vs €1.02 loss in FY 2020)

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Second quarter 2021 earnings released

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

New 90-day high: €10.60

Third quarter 2020 earnings released: €0.27 loss per share

Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020

Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport

Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency

New 90-day high: €11.85

Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands

Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation

First half earnings released

New 90-day low: €8.26

Centogene Opens Walk-In COVID-1 Testing Facility At Düsseldorf Airport

Centogene N.V. to Report First Half, 2020 Results on Sep 23, 2020

New 90-day low - €8.96

マネジメント基準チェック /24